Company: IMCR
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001140361-25-012123
Chunk: 35

Company: Immunocore Holdings plc
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 35
---
| • | is fully consistent with U.S. capital markets practice and governance standards. |

For the above reasons, our board of directors strongly recommends that you vote “FOR” resolutions 12 and 13. The full details of the resolutions are set forth below.

25

TABLE OF CONTENTS RESOLUTION 12 AUTHORIZATION OF ALLOTMENT OF SHARES The directors of an English public limited company must have specific authority from shareholders to allot shares in the company or to grant rights to subscribe for or convert any security into shares (“Share Rights”). At the 2021 GM, our shareholders authorized our directors to allot shares or to grant Share Rights up to an aggregate nominal amount of £150,000 (equal to 75 million ordinary shares with a nominal value of £0.002 each), for a period of up to five years until February 3, 2026. We are asking for your approval to renew the directors’ authority to allot shares for an additional five-year period to expire on May 14, 2030 in respect of shares or Share Rights with an aggregate nominal value of £150,000 (equal to 75 million ordinary shares with a nominal value of £0.002 each). Your approval of this resolution 12 will provide our board of directors with continued flexibility to issue shares or grant Share Rights up to such aggregate nominal value, subject to the shareholder approval and other requirements of Nasdaq and the SEC. The renewed authority would apply to the issuance of shares, grant of Share Rights, employee and director equity awards (except to the extent that they are granted under “employee share schemes” and therefore exempt from this requirement) and other securities convertible into or exercisable or exchangeable for our shares. Renewal of this authority would not exempt us from applicable Nasdaq requirements to obtain shareholder approval prior to certain share issuances or to comply with applicable SEC disclosure and other regulations, and our board of directors will continue to focus on and satisfy its fiduciary duties to our shareholders with respect to share issuances. If shareholders do not approve this resolution 12, the remaining unutilized authorization granted at the 2021 GM will continue to apply until the earlier of February 3, 2026 or such time as it has been fully utilized. Our board of directors will be, upon such expiry of authorization, constrained in its ability to fund the development of our business through equity offerings. Please see “Background to Resolutions 12 and 13—Share Issuance Authorization” for additional information regarding this resolution. Vote Required The